Disclosed is to a new pharmaceutical composition for oral administration containing sulfasalazine and/or a sulfasalazine organic salt, production processes and uses, in particular in the treatment of a disease or condition in which modulation of inflammatory cells is beneficial, a disease or condition concerning bones or joints and/or the gastro-intestinal tract.

An implantable device for delivery of a macromolecular drug compound is provided. The device comprises a core having an outer surface and a membrane layer positioned adjacent to the outer surface of the core. The core comprises a core polymer matrix within which is dispersed a drug compound having a molecular weight of about 0.5 kDa or more, the polymer matrix containing a hydrophobic polymer. Further, the membrane layer comprises a membrane polymer matrix within which the macromolecular drug compound is optionally dispersed. The membrane polymer matrix contains a hydrophobic polymer in combination with a hydrophilic compound, and the weight ratio of the hydrophobic polymer to the hydrophilic compound within the membrane polymer matrix ranges from about 0.25 to about 200.

A method of coating particles includes dispensing particles into a vacuum chamber to form a particle bed in at least a lower portion of the chamber that forms a half-cylinder, evacuating the chamber through a vacuum port in an upper portion of the chamber, rotating a paddle assembly such that a plurality of paddles orbit a drive shaft to stir the particles in the particle bed, injecting a reactant or precursor gas through a plurality of channels into the lower portion of the chamber as the paddle assembly rotates to coat the particles, and injecting the reactant or precursor gas or a purge gas through the plurality of channels at a sufficiently high velocity such that the reactant or precursor a purge gas de-agglomerates particles in the particle bed.

An encapsulated bacteriophage formulation and a method for encapsulating bacteriophages and bacteriophage-related products in polymeric microcapsules is provided. Some embodiments of the method of producing the encapsulated bacteriophages involves a water-in-oil-in-water double emulsion.

The present disclosure relates to microcapsules, methods of using such microcapsules in the delivery of drugs and probiotic microbes to subjects in need thereof, and methods of using such microcapsules for in vitro culture of microbes. In particular, the microcapsules comprise novel siloxane-based membranes that maintains transport properties essential to communication and growth of microbes.

Microparticulate drug compositions comprising nanocrystals of poorly soluble drugs combined with a carrier are disclosed. Also disclosed are pharmaceutical compositions that include the microparticulate drug compositions. Further disclosed are methods of preparing and using the microparticulate drug compositions/pharmaceutical compositions.

A microcapsule and a preparation method thereof, especially a multi-layer microcapsule containing an active substance and a preparation method thereof, the microcapsule having a single-layer or a multiple-layer encapsulation structure. A probiotic microcapsule and a preparation method thereof, the probiotic microcapsule having a single-layer or a multi-layer encapsulation structure. A food product or a health product containing a probiotic microcapsule (comprising a dairy product, a fermented-style food product, a beverage, chocolate, candy, a baked good, a fruit or vegetable juice product, etc. containing a probiotic microcapsule) and a preparation method thereof. A probiotic microcapsule soft powder and a preparation method thereof, the probiotic microcapsule soft powder comprising probiotic microcapsule nata de coco soft powder and probiotic microcapsule gel ball soft powder.

The present disclosure provides a method for producing an electrolyte solution which can contain a high concentration of microbubbles, and a method for producing a microbubble-containing solvent which can be used for preparing the electrolyte solution, by suppressing decrease in microbubbles during filtration.

The invention relates to coated particles with a taste-masked drug substance. The particles comprise a core with a melt-agglomerated active pharmaceutical ingredient (API), optionally a thermolabile API, and a coating comprising a triglyceride and a surfactant. The particles exhibit immediate drug release and a storage-stable release profile. Moreover, the invention provides a hot-melt granulation and hot-melt coating method for manufacturing such coated particles, and pharmaceutical compositions comprising the coated particles. The method allows the granulation of APIs with small particle sizes (e.g., mean particle size below 150 μm, or even below 100 μm or 50 μm) into core particles, as well as coating said core particles, at moderate temperatures, thereby preventing the degradation of thermolabile active pharmaceutical ingredients.

There is provided acid-resistant capsules, and in particular acid-resistant, vegetarian-based, and/or gelatin-based soft gel capsules and method of manufacturing the soft gel capsule. The soft gel capsule has 30% wt. to 45% wt. water; 15% wt. to 19% wt. glycerol; and a gel mass composition comprising a gelling agent and an alkaline agent. The method of manufacturing the capsule involves: dissolving a gelling polymer into water to form an enteric polymer solution; mixing an acid insoluble polymer with an alkali agent to form a film forming polymer; and adding the film forming polymer to the enteric polymer solution while mixing and heating at 70° C. until a gel mass forms.